CoChat

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer

Open access

The DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.

Abstract

Introduction CDKN2A (p16) inactivation is common in lung cancer and occurs via homozygous deletions, methylation of promoter region, or point mutations. Although p16 promoter methylation has been linked to KRAS mutation and smoking, the associations between p16 inactivation mechanisms and other common genetic mutations and smoking status are still controversial or unknown.Methods We determined all three p16 inactivation mechanisms with the use of multiple methodologies for genomic status, methylation, RNA, and protein expression, and correlated them with EGFR, KRAS, STK11 mutations and smoking status in 40 cell lines and 45 tumor samples of primary non-small-cell lung carcinoma. We also performed meta-analyses to investigate the impact of smoke exposure on p16 inactivation.Results p16 inactivation was the major mechanism of RB pathway perturbation in non-small-cell lung carcinoma, with homozygous deletion being the most frequent method, followed by methylation and the rarer point mutations. Inactivating mechanisms were tightly correlated with loss of mRNA and protein expression. p16 inactivation occurred at comparable frequencies regardless of mutational status of EGFR, KRAS, and STK11, however, the major inactivation mechanism of p16 varied. p16 methylation was linked to KRAS mutation but was mutually exclusive with EGFR mutation. Cell lines and tumor samples demonstrated similar results. Our meta-analyses confirmed a modest positive association between p16 promoter methylation and smoking.Conclusion Our results confirm that all the inactivation mechanisms are truly associated with loss of gene product and identify specific associations between p16 inactivation mechanisms and other genetic changes and smoking status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e3182a46c0c

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 114

Metadata

Authors
Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., Selamat, S. A., Laird-Offringa, I. A., Taguchi, A., Hanash, S., Shames, D., Ma, X., Zhang, M. Q., Lam, W. L., & Gazdar, A.
Affiliations
  • BC Cancer Agency (CA)
  • The University of Texas Southwestern Medical Center (US)
  • The University of Texas at Dallas (US)
  • Texas Scottish Rite Hospital for Children (US)
  • University of Southern California (US)
  • Fred Hutch Cancer Center (US)
  • Genentech (US)
Corresponding author
Gazdar, Adi
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2013-11
Volume
8
Issue
11
Pages
1378-1388
ISSN
1556-0864 (ISSN-L)
OpenAlex
W1971623971
Cited by
109
References
58
Citations by year
2026: 7 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 1 · 2014: 5
FWCI
0.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Thoracic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Canary Foundation
  • University of Texas Southwestern Medical Center (P50CA70907)
  • National Institutes of Health
  • National Human Genome Research Institute (R01HG001696, HG001696)
  • National Cancer Institute ((P50-CA70907, P50CA070907, U01CA086402)
  • National Institute of Environmental Health Sciences (U01ES017166)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
CDKN2A, p16, non-small cell lung cancer, p16 promoter methylation, homozygous deletion, smoking, KRAS mutation, EGFR mutation, STK11 mutation, Rb pathway, tumor suppressor inactivation, gene expression loss
MeSH terms
AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Prognosis, Proto-Oncogene Proteins, Smoking, Tumor Cells, Cultured, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Carcinoma, Adenosquamous, Carcinoma, Large Cell, ras Proteins, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, DNA Copy Number Variations, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1097/jto.0b013e3182a46c0c
The paper
Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., Selamat, S. A., Laird-Offringa, I. A., Taguchi, A., Hanash, S., Shames, D., Ma, X., Zhang, M. Q., Lam, W. L., & Gazdar, A. (2013). CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e3182a46c0c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.